Waldenström's macroglobulinemia (WM) is an uncommon lymphoma characterized by the infiltration of the bone marrow by clonal lymphoplasmacytic cells that produce monoclonal IgM. The disease may have an asymptomatic phase or patients may present with symptoms and complications due to marrow or other tissue infiltration or due to physicochemical or immunological properties of the monoclonal IgM. Diagnosis of WM has been clearly defined and genetic testing for somatic mutation of MYD88 L265P is a useful tool for the deferential diagnosis from other conditions and specific criteria that define symptomatic disease that needs treatment offer clinical guidance. The treatment of WM has evolved rapidly, with treatment options that include anti-CD20 monoclonal antibody-based combinations and BTK inhibitors. The choice of therapy is based on the need for a rapid disease control, presence of specific disease complications and patient's age. With the use of BTK inhibitors, the use of continuous therapy has been introduced as another option over fixed duration therapy. In this review we will focus on different clinical scenarios and discuss treatment options, based on the available data.
Introduction
Waldenström's macroglobulinemia (WM) is an uncommon lymphoma (~1%-2% of hematological malignancies) with unique features, characterized by the accumulation of lymphoplasmacytic cells that produce monoclonal IgM. Symptoms and complications are related to tumour burden or to the quantity, physicochemical or immunological properties of monoclonal IgM (Table 1) but the disease may also have a long asymptomatic course. WM is mostly a disease of the elderly 1,2 , has higher prevalence among Caucasians 1 and a familial predisposition 3, 4 . 
Diagnosis
The diagnosis of WM requires a bone marrow (BM) biopsy showing infiltration by clonal lymphoplasmacytic cells/lymphoplasmacytic lymphoma (LPL) and the presence of any amount of monoclonal IgM 5, 6 , detected by immunofixation electrophoresis. There is no threshold for BM clonal cell infiltration but individuals with <10% clonal cells have an indolent course 7 , compared to those with >=10% infiltration 8 . Two types of clonal cells (Bcells and a plasma cells with varying degree of differentiation 5, 9 ) are usually found. A LPL without monoclonal IgM present or secreting monoclonal non-IgM are not WM, although the biology may not differ significantly. A monoclonal IgM without LPL histopathology in the BM is not WM, but either a monoclonal gammopathy of undetermined significance (MGUS), or a nodal lymphoma without BM infiltration. Patients not fulfilling WM criteria may still need treatment for IgM-related complications. Table 2 shows the typical WM morphology and immunophenotype 5,6,9 and differential diagnosis. In 80%-95% of patients the lymphoplasmacytes harbour a somatic mutation in the myeloid differentiation primary response gene (MYD88 L265P ) 10 ; however, frequency varies according to detection method and DNA source (whole BM, CD19-selected cells, paraffin-embedded tissue, peripheral blood etc) 11, 12 . Detection in peripheral blood using cell free DNA is feasible, although with less sensitivity than in the bone marrow 13 . MYD88 L265P detection is helpful to differentiate WM from morphologically similar lymphomas or IgM myeloma, but, MYD88 L265P alone is not diagnostic of WM. Absence of MYD88 L265P does not exclude WM: 5%-10% of WM patients do not have MYD88 L265P (have other MYD88 mutations 14 or have wild type MYD88).
MYD88 L265P is found also in 30%-80% of IgM MGUS cases 10, 13, 15 (depending on method's sensitivity) and in other lymphomas, but at significantly lower rates. In 20%-40% of patients, lymphoplasmacytes have somatic activating mutations in the C-terminal domain of C-X-C chemokine receptor type 4 (CXCR4) gene 10, 16 , which are similar to germline mutations observed in WHIM syndrome (CXCR4 WHIM ). These heterogeneous mutations may be either truncating or frameshift, with potentially different clinical impact 17 , but are not helpful for WM diagnosis. Table 3 shows the tests that could be helpful in patients with WM. Anemia or anemia-related fatigue should be evaluated whether is due to WM or to other reasons (for example iron deficiency 18 ). Lactate dehydrogenase (LDH), serum albumin and beta-2 microglobulin are of prognostic significance. Evaluation of monoclonal IgM and other immunoglobulins are essential; uninvolved immunoglobulins are often suppressed 19 .
Initial work-up
Determination of IgM is more accurate with densitometry than total serum IgM by nephelometry 20 ; the same method should be used for comparisons and evaluation of response.
For personal use only. on September 18, 2019. by guest www.bloodjournal.org From Serum free light chains are commonly altered and may be more useful to follow patients that developed light chain (AL) amyloidosis. Renal dysfunction may be present and several renal pathologies have been described 21, 22 . Hyperviscosity syndrome related to high IgM levels is a hallmark of symptomatic WM, but there is no linear association of IgM levels with serum viscosity and hyperviscosity symptoms (headaches, blurred vision, confusion, epistaxis, gingival hemorrhages). A funduscopic examination is more reliable for detection of clinically significant hyperviscosity 23 .
Peripheral neuropathy is common and often the only indication to start treatment in otherwise asymptomatic patients. Neuropathy is usually sensory, symmetrical, ascending, starting from the feet, demyelinating 24 and typically slowly progressing. Rapidly progressing neuropathy should alert for alternate causes. High serum titters of myelin-associated globulin antibodies (anti-MAGs) are found in ~50% of these patients 25 . Less often, anti-ganglioside M1 (GM1) antibodies may be found, but in such cases motor neuropathy predominates.
Nerve conduction studies may show axonal degeneration in patients with longstanding sensorimotor neuropathy or amyloidosis; small fiber neuropathy may also be seen. There may be other unrelated causes for neuropathy, especially in older patients and consultation with a neurologist is advised. Amyloidosis may complicate WM, affecting kidneys, heart, liver and nerves 26 ; AL is the most common type in WM 26 , but others (such as AA) have been described. In case of isolated cardiac involvement in an elderly male WM patient, evaluation for ATTRwt should also be performed 27 . Computed tomography (CT) or magnetic resonance imaging (MRI) are useful for evaluation of organomegaly and lymphadenopathy. Positron emission tomography (PET) does not seem to offer additional information 28 , but, if transformation to an aggressive lymphoma or another malignancy is suspected, PET/CT may be used to biopsy the most FDG-avid lesion.
Case 1:
Patient's hemoglobin is 14.2 gr/dl, has no B-symptoms, splenomegaly or lymphadenopathy. A BM biopsy showed 50% infiltration by lymphoplasmacytes; molecular testing revealed MYD88 L265P .
Indications for Therapy
About 19-28% of patients have asymptomatic WM 8, 29 and can remain asymptomatic for several years; median time to symptom development may exceed 5-10 years 8, 30, 31 . Table 4 depicts indications to start therapy 31, 32 ; however, clinical judgement is required. The level of monoclonal IgM alone is not an indication to start treatment 31, 32 ; however, among those with high IgM levels (>6000 mg/dl) data are conflicting 33, 34 . Our approach is to follow closely such patients. Recently, a score based on BM infiltration percentage, IgM levels, b2microglobulin and albumin was developed that identified 3 groups of asymptomatic WM with For personal use only. on September 18, 2019. by guest www.bloodjournal.org From a median time to development of symptomatic disease of 1.8, 4.8 and 9.3 years 7 . There is no data to support early initiation of therapy over a watch and wait strategy, even in patients at high risk for progression; such patients should be managed in clinical trials. The patient in case 1 was asymptomatic at initial evaluation and according to the score above at intermediate risk. A close follow up and clinical evaluation is important and he was followed clinically at 3-month intervals, at least for the first couple of years, to evaluate the pace of the disease.
Risk assessment in symptomatic WM
A prognostic system (IPSSWM) based on age, b2-microglobulin, hemoglobin, platelet counts and IgM level stratifies patients into 3 risk groups 35 . Recently, a revised score (rIPSSWM) was developed 36 based on age, b2-microglobulin, serum LDH and albumin, and identifies 5 prognostic groups. In IPSSWM and rIPSSWM, age is a critical prognostic determinant and both are based on biochemical parameters and not on molecular or genetic characteristics. There is limited data on the prognostic impact of cytogenetics by interphase FISH or karyotype. The most common abnormality is del6q but has no proven prognostic impact 37 . Mutations/deletions of p53 are associated with poor prognosis 38 but are uncommon and rarely evaluated in clinical practice.
Therapies for WM
WM is a rare disease and few randomized trials have been conducted. No approved drugs or combination existed for WM until recently, when FDA and EMA approved ibrutinib.
Most data come from phase 2 studies and cross-trial comparisons and there are very few studies directly comparing different regimens ( Table 5 ).
The most rapidly acting therapy, whenever immediate IgM reduction is required Rituximab-based combinations are the most commonly used systemic therapies 40 .
Rituximab monotherapy is slow to act; an extended regimen (8 infusions) has better activity.
A transient increase of serum IgM ('IgM flare') is common, occurring in 30%-80% of patients treated with rituximab or other anti-CD20 monoclonal antibodies, and may exacerbate IgM-related complications 41, 42 . Rituximab with oral or intravenous cyclophosphamide and dexamethasone (DRC, for six cycles) remains a commonly used regimen with low short and long-term toxicity but responses may delay for months, complete responses are rare, and IgM flare is common 43 . Bendamustine with rituximab (BR, for four to For personal use only. on September 18, 2019. by guest www.bloodjournal.org From six cycles) is active (response rates ~90%, including some CRs) and with long lasting responses 44, 45 . In older patients bendamustine dose reductions are required and up to four cycles of BR may be sufficient since hematologic toxicity and infectious complications are common [45] [46] [47] . There is limited data on IgM flare in patients treated with BR.
Bortezomib has shown activity in several phase 2 studies, either alone or in combination with rituximab (VR or BDR), in newly diagnosed or relapsed patients 48-51 , does not cause IgM flare, can rapidly reduce IgM levels, but, marrow clearance may lag behind when used alone 52 . Today, bortezomib is administered subcutaneously and in weekly intervals 49,50,53 to reduce neurotoxicity. These fixed duration alkylator-free regimens, even without maintenance, offer prolonged PFS 48,54 . A randomized prospective study (ECWM-1) comparing DRC to DRC with bortezomib in previously untreated symptomatic patients has completed accrual. The non-neurotoxic, proteasome inhibitor carfilzomib has been tested in combination with rituximab in a small trial, but carfilzomib may be associated with a risk of cardiotoxicity 55 . Ixazomib, an oral proteasome inhibitor structurally similar to bortezomib, could be useful in WM but data are immature; it was evaluated in combination with rituximab and dexamethasone in previously untreated patients with response rates similar to bortezomib-rituximab 56 while another study evaluates ixazomib/dexamethasone with rituximab in patients with relapsed WM.
Combinations of nucleoside analogues with rituximab 57-59 are very active, but have significant short and long term toxicity and are not primary options [58] [59] [60] . Combinations with intensive chemotherapy, such as R-CHOP, are only considered if transformation to DLBCL occurs. Single agent chemotherapy is rarely considered but single agent oral fludarabine is more effective than chlorambucil 61 .
Ibrutinib is the most active single agent in WM 62,63 but complete responses are rare either as monotherapy or when combined with rituximab 64 . In the prospective randomized iNNOVATE trial, ibrutinib with rituximab was compared to extended schedule rituximab with placebo in previously untreated or pre-treated WM 64 . Ibrutinib-rituximab combination reduced the risk of disease progression by 80%. In previously untreated patients ibrutinib monotherapy resulted in high response rates (no CRs); these occurred slower in those carrying CXCR4 WHIM but the follow up is still short 65 . Ibrutinib is active in both rituximab sensitive and rituximab refractory patients 62, 63 . In the initial phase 2 study, 5-year PFS was 60% and 5-year OS was 87%, but, responses and PFS were better in patients with MYD88 L265P /CXCR4 WT than MYD88 L265P /CXCR4 WHIM genotype; among the few patients with MYD88 WT the responses were minor and PFS short 14 . In the iNNOVATE study, ibrutinib/rituximab treated patients harboring CXCR4 WHIM had lower VGPR rates and shorter PFS at 3 years but those with MYD88 WT had similar outcomes to MYD88 L265P . Ibrutinib is associated with a risk of atrial fibrillation (in ~10-12% of patients) 64 , hemorrhages (usually For personal use only. on September 18, 2019. by guest www.bloodjournal.org From minor but risk increases with anticoagulants ), has several interactions with commonly used drugs (antibiotics, anti-arrhythmics etc) and requires continuous uninterrupted therapy. An "ibrutinib withdrawal" syndrome can occur, characterized by B-symptoms and IgM rebound in ~20% of patients that interrupt ibrutinib for unrelated reasons 66, 67 ; however, most patients recover upon re-initiation and eventually re-achieve IgM response 67 . Two new BTK inhibitors are tested in WM in phase 2 (acalabrutinib) or phase 3 studies (zanabrutinib compared to ibrutinib).
Other drugs classes that have been tested in phase 2 studies with some efficacy but also with toxicity, include everolimus (alone 68 or in combinations 69 ) and IMiDs (thalidomide 70 , lenalidomide 71,72 ). Given the available treatment options these drugs are seldom considered for salvage therapy.
Choosing primary therapy
Patients with WM may present with a variety of symptoms and complications (Table   1 ) sometimes requiring immediate disease control. The goal of therapy is to control symptoms and reduce tumor burden; a complete response is difficult to achieve with current therapies.
In patients presenting with high tumor bulk (extensive organomegaly/lymphadenopathy, BM infiltration, high b2-microglobulin, elevated LDH, B-symptoms) rapidly acting regimens are preferred. If organomegaly, lymphadenopathy and B-symptoms predominate, then, BR or ibrutinib/rituximab may be preferable. In patients with cytopenias, bortezomib/rituximab(+/dexamethasone) or ibrutinib/rituximab may be preferred over BR due to lower myelotoxicity.
For patients presenting with or at risk for hyperviscosity, severe cryoglobulinemia or cold agglutinin disease, plasmapheresis should be considered. A regimen containing bortezomib, including a short induction before starting rituximab 53 or, ibrutinib, can rapidly reduce IgM levels and risk of IgM-flare 64 . When rapid reduction of toxic IgM is needed (as in AL amyloidosis, cryoglobulinemia, cold agglutinin disease 73 ), regimens such as BR 74 or BDR 53 are better options; ibrutinib may be less preferable in patients with cardiac amyloidosis due to the risk of AF 75 . In patients not in need for immediate disease control (low tumor bulk, or with mild cytopenias or mild symptoms) DRC, which has low toxicity, provides a safe, low cost, fixed duration option; BR is very active but may be more toxic (Figure 1 ). protocols, fludarabine has shown activity 79 , but, ibrutinib and other BTKis, penetrate the blood-brain barrier, have shown promising activity 80 and may be a primary option.
Age critically influences treatment selection. Short-term toxicity is a major concern in the elderly due to frailty, while, WM-unrelated mortality is significant 2 ; symptom and disease control should be the initial goal for most. Less toxic combinations such as DRC are well tolerated, BR requires dose reductions, BDR carries a risk of neuropathy. Ibrutinib (monotherapy or with rituximab) is very active but the risk of AF is higher in the elderly 81, 82 and treatment may be challenging in those with cardiac comorbidities or in need for anticoagulation or double-antiplatelet therapy or those receiving drugs that interact with ibrutinib. In younger patients, deeper responses may be the goal, short-term toxicity is better tolerated but long-term toxicity (secondary malignancies, MDS, disease transformation due to exposure to alkylators, nucleoside analogues or prolonged immunosuppression) is of concern; thus, alkylator-free regimens such as BDR, may be preferable. BR and DRC also have relatively low long-term toxicity. Ibrutinib has not been associated with MDS risk or disease transformation, but long-term effects are not fully known.
After the introduction of ibrutinib, the concept of continuous vs fixed duration therapy has emerged. Both approaches have pros and cons. Ibrutinib induces rapid responses but therapy continues uninterrupted for years (unknown for how long), the previously described toxicities may complicate therapy in elderly frail patients, perhaps some currently unknown long-term risks may exist while the financial burden is high. Approaches to limit the need for continuous therapy by combining BTKs with other drugs (venetoclax, proteasome inhibitors etc.) are ongoing. Rituximab-based chemo-immunotherapy is given for a fixed, limited duration, usually few months, with some patients receiving also fixed duration maintenance (Table 5) , with a relatively long treatment-free interval, and wellrecognized short-and long-term risks.
How I treat
Case 1: About 18 months after initial diagnosis, he complained for worsening fatigue and low-grade fever. IgM is 4.4 gr/dl but his hemoglobin is 11.8 gr/dl. Per IPSSWM is low risk and per rIPSSWM is low risk (has a score of 1).
Our primary consideration is to assess the need for rapid disease control and patient's age. For most patients our primary choice is a rituximab-based, fixed duration therapy, offering a treatment-free interval of several years (Table 5 & Figure 1 ). This young patient started therapy with BDR, achieved a rapid response and completed 6 cycles, without maintenance.
For personal use only. on September 18, 2019. by guest www.bloodjournal.org From Although maintenance rituximab could provide some clinical benefit according to retrospective data 83 , cannot be recommended due to the lack of prospective data in WM; the results of the MAINTAIN study that compares two years of rituximab maintenance vs no maintenance after BR are awaited. An approach based on ibrutinib (monotherapy 62 or with rituximab 64 ) may also be considered. Concurrent use of ibrutinib with anticoagulation is challenging and thrombotic risk should be weighed against bleeding risk (with tools such as CHA 2 DS 2 -VASc and HAS-BLED) and potential alternative treatment options. There are data from ibrutinib-treated CLL patients and expert opinions [84] [85] [86] regarding the management of such patients, but often the recommendations are conflicting 87 . In our practice, we prefer to use apixaban or dabigatran (which also has an antidote available) at lower doses.
Case 3:
A 76-year-old gentleman with a history of heart failure due to CAD and valvular heart disease, was admitted for dyspnea. Anemia (hemoglobin 8.3 gr/dl), thrombocytopenia (platelet counts 88x10 9 /L), oronasal bleeding, high serum total protein (13.4 gr/dl), low serum albumin (2.6 gr/dl) were noted. SPEP revealed monoclonal IgM(κ) (~8.1 gr/dl). A BM biopsy revealed lymphoplasmacytic infiltration~90%. CT showed increased spleen size and multiple small lymph nodes in the mediastinum and abdomen.
For this patient, ibrutinib may not be the best option due to cardiac comorbidities. He received two plasmapheresis sessions to control hyperviscosity symptoms and started bortezomib; after 4 weekly bortezomib administrations, rituximab was added and has completed 4 cycles of BDR. Another option could also be BR, at reduced doses.
For personal use only. on September 18, 2019. by guest www.bloodjournal.org From Case 4: A 74-year-old lady was diagnosed with WM, 7 years ago; she had anemia (hemoglobin 9.8 gr/dl), 2.5 gr/dl of IgM(κ) and BM had 80% LPL infiltration . She received 6 cycles of DRC, IgM dropped to 0.9 gr/dl, hemoglobin increased (12.6 gr/dl). Eighteen months ago, a gradual increase of IgM was noted and lately she feels fatigued. Hemoglobin is 10.1 gr/dl and IgM is 2.4 gr/dl. The criteria to start therapy in newly diagnosed apply also in relapsing patients, but clinical judgment is important. For patients that relapse after a long remission following a rituximab-containing regimen (i.e. at least 3 years, the median expected for regimens like DRC), a second attempt to achieve another prolonged remission with the initial or different rituximab-based regimen (bendamustine instead of cyclophosphamide 88 or a proteasome inhibitor 49 ) is reasonable, but no prospective randomized data exist (Table 5 & Figure 2 ).
Combinations with a nucleoside analogue 57,58 are effective, but carry significant risk of myelotoxicity and MDS 58, 89 , and we rarely use them. Ibrutinib alone 62 or in combination with rituximab 64 is very active. There is no direct comparison of Ibrutinib/rituximab with ibrutinib alone in WM. Data from CLL indicate that probably there is no difference, but, according to iNNOVATE data, in patients with MYD88 WT ibrutinib with rituximab may be preferable to ibrutinib alone 64 since these patients seem to have similar outcomes to those bearing MYD88 L265P . We do not choose therapy based on CXCR4 status; however, for patients with unknown MYD88 mutational status, we recommend testing prior to initiation of ibrutinib therapy. For patient 4, repeating DRC 43 or starting BR was discussed. She received BR (bendamustine 70 mg/m 2 ) for 4 cycles, achieved a PR and her hemoglobin improved; IgM continued to drop for 9 months after BR completion and remains in remission for 28 months.
Case 1:
The patient relapsed 14 months after completion of primary therapy with BDR.
Repeat genotyping showed MYD88 L265P and no CXCR4 WHIM .
In patients who relapse >12 months after last rituximab dose, but in whom the duration of remission was <3 years, ibrutinib (+/-rituximab) may be the most active therapy.
Another rituximab-based regimen, different than the one previously used, may be considered also. Although has not been directly compared to regimens such as BR or BDR, ibrutinib is probably more effective in this patient population. For this patient, potential options included a combination of chemotherapy with rituximab or ibrutinib. Due to his young age, avoiding exposure to chemotherapy was felt to be important and started ibrutinib with excellent tolerability and response.
If disease progresses during rituximab therapy or <12 months after last rituximab dose then WM is considered as "rituximab resistant". However, IgM flare may falsely give An emerging challenge is the management of patients progressing during ibrutinib therapy or discontinuing due to toxicity. In a recent phase 2 study, among 30 patients with relapsed/refractory WM (15 had prior ibrutinib), single agent venetoclax induced responses in 93%, which were more frequent and deeper in ibrutinib-naïve patients 93 . Venetoclax has been approved for the treatment of CLL and could be an option for patients failing ibrutinib. Many patients failing ibrutinib can be salvaged with rituximab-based chemoimmunotherapy 67 , but their outcome is often poor; participation in clinical trials with new agents is the best option. Physicians should educate their patients to adhere to standard screening for solid tumors, and evaluate appropriately anemia or cytopenias, not related to disease progression.
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Conclusions
Many options that fit different WM patients' needs are available. The major challenge is the development of active, low toxicity combinations that will provide a high probability of complete responses, potentially with a fixed duration of therapy. New new treatments are emerging but available therapies can be further optimized. Inclusion in clinical trials offers the best opportunity for patients to receive new therapies, and for most patients this would be our preferred choice. Despite recent advances, we need deeper understanding of the disease and international collaboration in clinical trials in order to improve therapy. For personal use only. on September 18, 2019. by guest www.bloodjournal.org From Figure 1 : management of WM: choice of therapy in previously untreated and previously treated patients Figure 2 : management of patients that relapse after rituximab-based therapy. For patients that relapse after ibrutinib or discontinue ibrutinib for reasons such as toxicity, there are limited data and venetoclax or anti-CD20 monoclonal antibody with chemotherapy or proteasome inhibitors may be considered, depending on the availability of venetoclax and other drugs 
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